Who's who · AI in biology and medicine
Insilico Medicine
Insilico Medicine uses generative AI to find drug targets and design molecules, with operations in the US and Hong Kong.
Why it matters: Its rentosertib is among the most advanced drugs both discovered and designed with generative AI.
Key facts
- Signed an AI drug-discovery deal with Eli Lilly in March 2026 worth up to $2.75 billion, including $115 million upfront.Source: en.wikipedia.org, as of Mar 2026
- Its experimental drug rentosertib was in a Phase 3 trial as of 2026.Source: en.wikipedia.org, as of Jun 2026
- Is listed on the Hong Kong Stock Exchange under ticker 3696.Source: en.wikipedia.org, as of Nov 2026
Our latest stories
No stories about Insilico Medicine in our recent coverage yet. New ones appear here as they publish.